ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011
"Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 90 citations in OpenAlex.
- Modern Approaches and Emerging Biological Therapies to Treat Fracture Nonunion.Pharmaceutics · 2025Review
- Regional Gene Therapy for Bone Tissue Engineering: A Current Concepts Review.Bioengineering (Basel, Switzerland) · 2025Review
- Article
- Biodistribution of lentiviral transduced adipose-derived stem cells for "ex-vivo" regional gene therapy for bone repair.Gene therapy · 2023Article
- Delivery of Growth Factors to Enhance Bone Repair.Bioengineering (Basel, Switzerland) · 2023Review
- Sema3A Modified PDLSCs Exhibited Enhanced Osteogenic Capabilities and Stimulated Differentiation of Pre-Osteoblasts.Cell biochemistry and biophysics · 2023Article
- Influence of donor age and comorbidities on transduced human adipose-derived stem cell in vitro osteogenic potential.Gene therapy · 2023Article
- Gene Therapy for Regenerative Medicine.Pharmaceutics · 2023Review
- Osteochondrogenesis by TGF-β3, BMP-2 and noggin growth factor combinations in anFrontiers in bioengineering and biotechnology · 2023Article
- Effects of cell seeding technique and cell density on BMP-2 production in transduced human mesenchymal stem cells.Journal of biomedical materials research. Part A · 2022Article
- 3D-Printing for Critical Sized Bone Defects: Current Concepts and Future Directions.Bioengineering (Basel, Switzerland) · 2022Review
- Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation.Frontiers in bioengineering and biotechnology · 2022Review
- Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications.Gene therapy · 2021Article
- Regional Gene Therapy with Transduced Human Cells: The Influence of "Cell Dose" on Bone Repair.Tissue engineering. Part A · 2021Article
- Gene therapy for bone healing: lessons learned and new approaches.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Orthopaedic Gene Therapy: Twenty-Five Years On.JBJS reviews · 2021Article
- Article
- Gene expression profiling of progenitor cells isolated from rat rotator cuff musculotendinous junction.BMC musculoskeletal disorders · 2020Article
- Comparison of experimental peri-implantitis models after application of ex vivo BMP2 gene therapy using periodontal ligament stem cells.Scientific reports · 2020Article
- Silencing MicroRNA-137-3p, which Targets RUNX2 and CXCL12 Prevents Steroid-induced Osteonecrosis of the Femoral Head by Facilitating Osteogenesis and Angiogenesis.International journal of biological sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Ex-vivo regional gene therapy with bone marrow cells (BMCs) overexpressing bone morphogenetic protein-2 (BMP-2) has demonstrated efficacy in healing critical sized bone defects in preclinical studies. The purpose of this preclinical study was to compare the osteoinductive potential of a novel "same day" ex-vivo regional gene therapy versus a traditional two-step approach, which involves culture expansion of the donor cells before implantation. In the "same day" strategy buffy coat cells were harvested from the rat bone marrow, transduced with a lentiviral vector-expressing BMP-2 for 1 hour and implanted into a rat femoral defect in the same sitting. There was no significant difference (P = 0.22) with respect to the radiographic healing rates between the femoral defects treated with the "same day" strategy (13/13; 100%) versus the traditional two-step approach (11/14; 78%). However, the femoral defects treated with the "same day" strategy induced earlier radiographic bone healing (P = 0.004) and higher bone volume (BV) [micro-computed tomography (micro-CT); P < 0.001]. The "same day" strategy represents a significant advance in the field of ex-vivo regional gene therapy because it offers a solution to limitations associated with the culture expansion process required in the traditional ex vivo approach. This strategy should be cost-effective when adapted for human use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.